Cibus

CBUS

Market cap $209M

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report fourth quarter 2025 financial results on Tuesday, March 17, 2026. Cibus' management team will host a conference call and audio webcast at 4:30 p.m.

Cibus to utilize proprietary Rapid Trait Development System™ to enable development of durable resistance to Light Leaf Spot disease, which has caused estimated yield losses of up to £300m in recent years

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced the pricing of an underwritten public offering of 13,333,333 shares of its Class A Common Stock, par value $0.0001 per share (“Class A Common Stock”), at a public offering price of $1.50 per share (the “Offering”). Members of Cibus' Board of Directors will purchase 1,000,000 shares of Class A Common Stock in the Offering at the public offering price.

SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that it intends to offer shares of its Class A common stock, par value $0.0001 per share (“Class A Common Stock”), in an underwritten public offering (the “Offering”). Cibus also expects to grant to the underwriter of the Offering a 30-day option to purchase up to an additional 15% of the shares of Class A Common Stock offered in the Offering on the same terms and conditions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed or as to the actual size or terms of the Offering. Members of Cibus' Board of Directors (collectively, the “Related Persons”) have indicated an interest in purchasing shares of Class A Common Stock in the Offering. Because these indications of interest are not binding agreements or commitments to purchase, those certain Related Persons may elect not to purchase any shares in the Offering, or the underwriter may elect not to sell any shares in the Offering to those certain Related Persons.

Nonbinding Letter of Intent (LOI) sets framework for potential 2027 market entry in Ecuador and Colombia, followed by expansion into Peru, Central America and the Caribbean Expected to build on success under the existing 2024 material transfer agreement, shifting focus to market execution and revenue generation for co-developed herbicide-tolerant (HT) rice traits SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, and Interoc, a leading provider of agricultural solutions in Latin America, today announced the execution of a non-binding Letter of Intent (LOI). The non-binding LOI establishes a potential framework for the commercialization of co-developed herbicide-tolerant (HT) rice traits in key rice-producing markets across Latin America.

Political agreement on New Genomic Techniques (NGTs), including gene editing, advances a science-based path for plant breeding innovation and supports Cibus' plans to bring improved traits to European growers

Cibus, Inc. ( CBUS ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Carlo Broos - Chief Financial Officer Peter Beetham - Co-Founder, Interim CEO, President, COO & Director Gregory Gocal - Co-Founder, Chief Scientific Officer & Executive VP Conference Call Participants Kevin Estok - Jefferies LLC, Research Division Matthew Venezia - Alliance Global Partners, Research Division Sameer Joshi - H.C. Wainwright & Co, LLC, Research Division Austin Moeller - Canaccord Genuity Corp., Research Division Alex Hantman - Sidoti & Company, LLC Presentation Operator Good afternoon, everyone, and welcome to the Cibus Third Quarter 2025 Results Conference Call.

Cibus (CBUS) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to earnings of $0.06 per share a year ago.

With the addition of Centro Internacional de Agricultura Tropical (CIAT) in the quarter, Cibus now has 5 LATAM Rice customers as momentum continues toward achieving 2027 targeted initial LATAM Rice revenue On track to deliver HT traits to Latin American customer in Q4 2025 with field trials expected to commence by year end Engaged strategic growth advisory firm AgVayā to introduce Indian Rice growers to new solutions to scale crop productivity through advanced gene editing Su ccessfully completed pre-commercial pilot runs for certain biofragrance products; commercial expansion targeted for 2026 Positive field trial results for HT2 in Canola in North America ; HT2 and Sclerotinia resistance traits available for seed licensing partners for funded continued development opportunity Initiated additional actions to support streamlined business focus prioritizing nearest-term and partner-funded commercial opportunities while the Company targets a reduced annual net cash usage of $30 million by 2026, and completed consolidation of Oberlin facility activities Appointed Kimberly A. Box and Craig Wichner to Cibus' Board of Directors, which strategically strengthens Cibus' commercial expansion support SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced its financial results for the quarter ended September 30, 2025, and provided a year-to-date business update for 2025.

Appointment underscores company's commitment to long-term shareholder value creation and sustained business growth Appointment underscores company's commitment to long-term shareholder value creation and sustained business growth